RxDoctor Payments Data

Nikki Neubauer, MD

Gynecologic Oncology · Oak Lawn, ILNPI 1598975336

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.8% of the total across 23 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Intuitive Surgical at 43.4% of the total. Reporting peaked in 2019 at $370 and has fallen 82.2% since, to $66 in 2025. That places this record below the midpoint for gynecologic oncology clinicians in IL, where the typical reported total is $1,540.

$672in general payments, 2019–2025

Across 23 payments — averaging $29.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$292
  • GSK$79
  • Myriad Genetic Laboratories, Inc.$52
  • Merck$44
  • Seagen Inc.$42
  • AstraZeneca$42
  • plus $122 from 7 others
$259,201in research payments, 2019–2025

Across 13 payments — averaging $19,939 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Tesaro, Inc.$259K

What the payments were for

  • Food & beverage$61091%
  • Education$629%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Intuitive Surgical4$292
GSK3$79
Myriad Genetic Laboratories, Inc.2$52
Merck3$44
Seagen Inc.2$42
AstraZeneca2$42
Tempus AI, Inc1$25
Eisai Inc.1$22
AbbVie1$19
Mylan Institutional Inc.1$15
Innovation Technologies Inc1$15
Clovis Oncology, Inc.1$13
Dysis Medical, Inc.1$13

How this compares

$672 in reported general payments places this provider in the 30th percentile of 64 gynecologic oncology providers in Illinois.

See all gynecologic oncology providers in Illinois

Medicare billing

Part B allowed, 2024
$2,089,317
Medicare patients
317
Services billed
58,301

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Metronidazole60$2,420
Clobetasol Propionate42$1,431
Enoxaparin Sodium11$849
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen111$679
Prednisolone Acetate12$373
Doxycycline Monohydrate28$293
Cephalexin46$284
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst19$269
Medroxyprogesterone Acetate36$238
Letrozole13$210
Ibuprofen57$167
Gabapentin20$83
Fluconazole13$76
Tramadol Hcl32$68

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Oak Lawn

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →